Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease
(2016) In Dementia and Geriatric Cognitive Disorders Extra 6(2). p.94-283- Abstract
BACKGROUND: Dysfunctions of the ubiquitin proteasome system (UPS), including the highly abundant neuronal enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and autophagy-related changes (lysosomal degradation) are implicated in several neurodegenerative disorders including Alzheimer's disease (AD).
METHOD: This study evaluated cerebrospinal fluid (CSF) levels of UCH-L1, protein deglycase (DJ-1), neuron-specific enolase (NSE), and tau phosphorylated at threonine 231 (P-tau231) in two independent patient and control cohorts. Cohort 1 included CSF samples from subjects having an AD biomarker profile (n = 10) or a control biomarker profile (n = 31), while cohort 2 was a monocenter clinical study including patients with AD (n =... (More)
BACKGROUND: Dysfunctions of the ubiquitin proteasome system (UPS), including the highly abundant neuronal enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and autophagy-related changes (lysosomal degradation) are implicated in several neurodegenerative disorders including Alzheimer's disease (AD).
METHOD: This study evaluated cerebrospinal fluid (CSF) levels of UCH-L1, protein deglycase (DJ-1), neuron-specific enolase (NSE), and tau phosphorylated at threonine 231 (P-tau231) in two independent patient and control cohorts. Cohort 1 included CSF samples from subjects having an AD biomarker profile (n = 10) or a control biomarker profile (n = 31), while cohort 2 was a monocenter clinical study including patients with AD (n = 32), mild cognitive impairment (n = 13), other dementias (n = 15), as well as cognitively healthy controls (n = 20).
RESULTS: UCH-L1 and P-tau231 were elevated in AD patients compared to controls in both cohorts. CSF levels of DJ-1 and NSE were unchanged in the AD group, whereas they were decreased in the group of other dementia compared to controls in the clinical study.
CONCLUSION: Our main findings support that the UPS pathway may be impaired in AD, and UCH-L1 may serve as an additional CSF biomarker for AD.
(Less)
- author
- Öhrfelt, Annika
; Johansson, Per
LU
; Wallin, Anders
; Andreasson, Ulf
; Zetterberg, Henrik
; Blennow, Kaj
and Svensson, Johan
- publishing date
- 2016-08-10
- type
- Contribution to journal
- publication status
- published
- keywords
- Journal Article
- in
- Dementia and Geriatric Cognitive Disorders Extra
- volume
- 6
- issue
- 2
- pages
- 12 pages
- publisher
- Karger
- external identifiers
-
- scopus:84978972848
- pmid:27504117
- ISSN
- 1664-5464
- DOI
- 10.1159/000447239
- project
- Endocrine and diagnostic aspects of cognitive impairment
- language
- English
- LU publication?
- no
- id
- 8dc8a8c7-7ebf-45f8-bcf1-7ed99c5f49be
- date added to LUP
- 2016-09-29 16:20:52
- date last changed
- 2025-12-14 17:20:03
@article{8dc8a8c7-7ebf-45f8-bcf1-7ed99c5f49be,
abstract = {{<p>BACKGROUND: Dysfunctions of the ubiquitin proteasome system (UPS), including the highly abundant neuronal enzyme ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and autophagy-related changes (lysosomal degradation) are implicated in several neurodegenerative disorders including Alzheimer's disease (AD).</p><p>METHOD: This study evaluated cerebrospinal fluid (CSF) levels of UCH-L1, protein deglycase (DJ-1), neuron-specific enolase (NSE), and tau phosphorylated at threonine 231 (P-tau231) in two independent patient and control cohorts. Cohort 1 included CSF samples from subjects having an AD biomarker profile (n = 10) or a control biomarker profile (n = 31), while cohort 2 was a monocenter clinical study including patients with AD (n = 32), mild cognitive impairment (n = 13), other dementias (n = 15), as well as cognitively healthy controls (n = 20).</p><p>RESULTS: UCH-L1 and P-tau231 were elevated in AD patients compared to controls in both cohorts. CSF levels of DJ-1 and NSE were unchanged in the AD group, whereas they were decreased in the group of other dementia compared to controls in the clinical study.</p><p>CONCLUSION: Our main findings support that the UPS pathway may be impaired in AD, and UCH-L1 may serve as an additional CSF biomarker for AD.</p>}},
author = {{Öhrfelt, Annika and Johansson, Per and Wallin, Anders and Andreasson, Ulf and Zetterberg, Henrik and Blennow, Kaj and Svensson, Johan}},
issn = {{1664-5464}},
keywords = {{Journal Article}},
language = {{eng}},
month = {{08}},
number = {{2}},
pages = {{94--283}},
publisher = {{Karger}},
series = {{Dementia and Geriatric Cognitive Disorders Extra}},
title = {{Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease}},
url = {{http://dx.doi.org/10.1159/000447239}},
doi = {{10.1159/000447239}},
volume = {{6}},
year = {{2016}},
}